Search this website. You can use fund codes to locate specific funds

Impact Report, Q1 2020

Diabetes is one of the world’s four major noncommunicable diseases – and the number of adults with the disease is rising rapidly. In our Q1 2020 report, we explore the diabetes epidemic and innovative solutions to tackle this unmet medical need.

Diabetes: a growing epidemic

In our latest Quarterly Impact Report, we explore the impact theme of health and well-being and demonstrate how two holdings are aligned to it.

Source: International Diabetes Federation, Financial Times, as at March 2020.

One of our current holdings is a  Danish multinational pharmaceutical company which provides products for all types of diabetes treatment needs including its new generation of glucagon-like peptide (GLP-1) products. GLP-1 drugs have better efficacy in managing blood glucose levels and lead to lower cardiovascular and severe hypoglycaemia risks. As such, the treatment has the potential to improve health outcomes with lower comorbidities, while its weight loss benefits could help tackle obesity by helping reset the metabolism to a lower basal rate.

Meanwhile, a US-based medical devices company, a recent addition to our portfolio, is leading the way in changing the standard of care for glucose monitoring in diabetes through its continuous glucose monitoring (CGM) devices. These devices can help sufferers better manage the disease and reduce the costs associated with it. It is the only pure play company in this fast-growing sector and currently holds about 70% market share of the insulin intensive segment in the US.

To find out more, read the full report.

Risk profile
  • This information does not constitute a solicitation or offer to any person to buy or sell any related securities or financial instruments.

More Insights

Authenticity in ESG integration
We explain why the delivery of Sustainable Wealth Creation has and always will be our core purpose.
Weekly Credit Insight
Dispersion in year-to-date returns across various parts of the global credit universe.
Zen and the art of investment management
Exploring mindfulness as a vehicle for truly responsible investing
Stewardship during a crisis: Lessons from the pandemic
Dr Hans-Christoph Hirt, Head of EOS, reflects on the pandemic and the stewardship lessons for companies and investors.
Pricing ESG risk in credit markets: through volatility, our conviction affirmed
Companies with better ESG practices tend to have lower CDS spreads, even after controlling for credit risks.
Credit Pulse: market update – 12 March 2021
How does the fixed-income team use different types of loans to protect investments from inflation in this current environment and why have asset-backed securities (ABS) grown more attractive as concerns over rates increase?